Introducing Deborah Zajac, SOSV’s newest general partner and member of the IndieBio NY team.

Bruce Donald, Marcel Frenkel and Mark Hallen are analyzing over 19,290,123 compounds per second at quantum accuracies to develop drugs to previously incurable cancers.

Zurich-based Oxyle recently raised a $16M seed round led by 360 Ventures with participation from Axeleo Capital, Founderful and SOSV, according to a report in Forbes. Water supplies around the world are contaminated with “Forever Chemicals,” or the 10,000 perfluoroalkyl and polyfluoroalkyl substances known by the acronym PFAS. They are linked to a sharp increases […]

In this video, SOSV partner and HAX Chief Science Officer Susan Schofer, PhD gives SOSV founder Sean O’Sullivan a tour of the HAX Analytics Laboratory.

Lady Technologies, Inc., the company behind kegg—a fertility tracking device that monitors cervical mucus—has secured $6.5 million in Series A led by Relentless Consumer Partners funding to advance women’s health by emphasizing the importance of cervical mucus and developing a comprehensive vaginal health platform. To date, kegg has supported 50,000 women and families on their trying-to-conceive journey. The […]

Please meet Katie Hoffman, who joined SOSV as our ninth General Partner and the fourth partner at HAX. Together with Andy Gollach, Susan Schofer, our Chief Science Officer, and Ji Ke, our Chief Technology Officer, we now have a 5-strong investment team at HAX in Newark.

Women’s health is gaining attention as a critical area for research, innovation, and investment. In its January 2024 report, McKinsey estimated that “Investments addressing the women’s health gap could add years to life and life to years—and potentially boost the global economy by $1 trillion annually by 2040”. Venture investment in startups focused on disease […]

Rybodyn, Inc. is making waves in biotech with its groundbreaking discovery of a cryptic human proteome and a $4 million pre-seed funding round.

Proton Intelligence has raised a $6.95M seed round to accelerate their work on a continuous potassium monitor that aims revolutionize clinical care for at risk patients.

Investors! Join IndieBio in New York on February 12, 2025 for Demo Day featuring 15 startups across climate and health.